Ignite Creation Date:
2025-12-24 @ 11:42 PM
Ignite Modification Date:
2026-02-08 @ 3:59 PM
Study NCT ID:
NCT02521051
Status:
TERMINATED
Last Update Posted:
2025-05-13
First Post:
2015-07-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}, {'id': 'D001932', 'term': 'Brain Neoplasms'}], 'ancestors': [{'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D016543', 'term': 'Central Nervous System Neoplasms'}, {'id': 'D009423', 'term': 'Nervous System Neoplasms'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C582670', 'term': 'alectinib'}, {'id': 'D000068258', 'term': 'Bevacizumab'}], 'ancestors': [{'id': 'D061067', 'term': 'Antibodies, Monoclonal, Humanized'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'jgainor@partners.org', 'phone': '617-724-4000', 'title': 'Justin Gainor, MD', 'organization': 'Massachusetts General Hospital'}, 'certainAgreement': {'piSponsorEmployee': True}, 'limitationsAndCaveats': {'description': 'Study was stopped prematurely because of slow accrual, leasing to small numbers of subjects analyzed.'}}, 'adverseEventsModule': {'timeFrame': 'up to 4 years', 'eventGroups': [{'id': 'EG000', 'title': 'Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg', 'description': 'Participants were administered Alectinib 600 mg twice daily by mouth, and Bevacizumab 15 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days).', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 6, 'seriousNumAtRisk': 6, 'deathsNumAffected': 1, 'seriousNumAffected': 1}, {'id': 'EG001', 'title': 'Phase II: RP2D', 'description': 'In the phase II portion of the study, all patients received alectinib plus bevacizumab at the RP2D determined in the phase I portion.', 'otherNumAtRisk': 5, 'deathsNumAtRisk': 5, 'otherNumAffected': 5, 'seriousNumAtRisk': 5, 'deathsNumAffected': 3, 'seriousNumAffected': 2}], 'otherEvents': [{'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 3}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Diarrhea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Proteinuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 2}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Edema limbs', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'CPK increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Aspartate aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Epistaxis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Hypophosphatemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Bilirubin increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Rash, maculopapular', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Anemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Respiratory, thoracic and mediastinal disorders - Other, specify', 'notes': 'Hemoptysis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Gastrointestinal disorders - Other, specify', 'notes': 'gingival bleeding', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Hematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Gastrointestinal disorders - Other, specify', 'notes': 'tongue sensitivity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Dysgeusia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Bloating', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Respiratory, thoracic and mediastinal disorders - Other, specify', 'notes': 'sinus congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Palpitations', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Memory impairment', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Flu-like symptoms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Creatinine increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Tremor', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Chest wall pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Musculoskeletal and connective tissue disorder - Other, specify', 'notes': 'Rotator cuff tendinopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Abdominal pain', 'notes': 'epigastric pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Non-cardiac chest pain', 'notes': 'Chest tightness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Abdominal infection', 'notes': 'diverticular abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Gastrointestinal disorders - Other, specify', 'notes': 'Aphthous ulcer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Blurred vision', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Allergic rhinitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Tinnitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Dry skin', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Skin infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 2}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Upper respiratory infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Infections and infestations - Other, specify', 'notes': 'thrush', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Mucositis oral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Pain', 'notes': 'elbow pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Hyperglycemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Sore throat', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Immune system disorders - Other, specify', 'notes': 'hypersensitivity reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Immune system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Urticaria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 2}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Esophagitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Hoarseness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Vascular disorders - Other, specify', 'notes': 'superior vena cava occlusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Lipase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Fever', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Dyspnea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}], 'seriousEvents': [{'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Proteinuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Pneumonitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 5, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': '(Phase 1) Recommended Phase II Dose of Alectinib', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg', 'description': 'Participants were administered Alectinib 600 mg twice daily by mouth, and Bevacizumab 15 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days).'}], 'classes': [{'categories': [{'measurements': [{'value': '600', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'first cycle of treatment (21 days)', 'description': 'The recommended phase II doses for the combination of alectinib and bevacizumab will be defined as either a) the highest dosage cohort in which less than 1/3 of patients experience a dose-limiting toxicity or b) alectinib at the previously defined recommended phase II dose (600 mg twice daily PO) as a single agent plus bevacizumab at the highest tolerated dose (15 mg/kg IV every 21 days) investigated in this indication - whichever is the lower dose.\n\nDose-limiting toxicities (DLTs) were defined as adverse events (AEs) occurring within the first cycle of treatment (21 days) attributed to the study drugs.', 'unitOfMeasure': 'mg', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': '(Phase 1) Recommended Phase II Dose of Bevacizumab', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg', 'description': 'Participants were administered Alectinib 600 mg twice daily by mouth, and Bevacizumab 15 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days).'}], 'classes': [{'categories': [{'measurements': [{'value': '15', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'first cycle of treatment (21 days)', 'description': 'The recommended phase II doses for the combination of alectinib and bevacizumab will be defined as either a) the highest dosage cohort in which less than 1/3 of patients experience a dose-limiting toxicity or b) alectinib at the previously defined recommended phase II dose (600 mg twice daily PO) as a single agent plus bevacizumab at the highest tolerated dose (15 mg/kg IV every 21 days) investigated in this indication - whichever is the lower dose.\n\nDose-limiting toxicities (DLTs) were defined as adverse events (AEs) occurring within the first cycle of treatment (21 days) attributed to the study drugs.', 'unitOfMeasure': 'mg/kg', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': '(Phase 2) Number of Participants With Intracranial Hemorrhagic Events Who Received RP2D', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase II: RP2D', 'description': 'In the phase II portion of the study, all patients received alectinib plus bevacizumab at the RP2D determined in the phase I portion.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'up to 4 years', 'description': 'In the phase II portion of the study, we aim to further investigate the safety and tolerability of alectinib plus bevacizumab at the RP2Ds as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The combination of alectinib and bevacizumab will be deemed unsafe if 2 or more participants are observed to have grade 2 or higher, central nervous system (CNS) intracranial hemorrhagic events.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'RP2Ds for alectinib plus bevacizumab were confirmed in August 2016. Enrollment for the phase II cohort occurred from August 2016 to February 2020. We initially planned to enroll 20 participants to the phase II cohort but due to slow accrual, the decision was made to stop the study prematurely in July 2021.'}, {'type': 'SECONDARY', 'title': 'Central Nervous System Objective Response Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg', 'description': 'Participants were administered Alectinib 600 mg twice daily by mouth, and Bevacizumab 15 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days).'}, {'id': 'OG001', 'title': 'Phase II: RP2D', 'description': 'In the phase II portion of the study, all patients received alectinib plus bevacizumab at the RP2D determined in the phase I portion.'}], 'classes': [{'categories': [{'measurements': [{'value': '66.66', 'groupId': 'OG000'}, {'value': '60.00', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Up to 4 years', 'description': 'Objective response rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR), evaluated using a modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria for CNS response:\n\n* CR = Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to less than 10 mm.\n* PR = At least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Central Nervous System Disease Control Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg', 'description': 'Participants were administered Alectinib 600 mg twice daily by mouth, and Bevacizumab 15 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days).'}, {'id': 'OG001', 'title': 'Phase II: RP2D', 'description': 'In the phase II portion of the study, all patients received alectinib plus bevacizumab at the RP2D determined in the phase I portion.'}], 'classes': [{'categories': [{'measurements': [{'value': '100', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Up to 4 years', 'description': 'Disease control rate (DCR) is the percentage of participants with intracranial complete response (CR), partial response (PR), and stable disease (SD), evaluated using a modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria for CNS response:\n\n* CR = Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to less than 10 mm.\n* PR = At least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters.\n* SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the baseline sum diameters.\n* PD = At least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. At least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions also qualifies as PD.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "One participant from the phase 1 cohort was excluded from analysis because they didn't have an intracranial lesion(s) at enrollment, nor did they develop any while on study."}, {'type': 'SECONDARY', 'title': 'Central Nervous System Progression-free Survival', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg', 'description': 'Participants were administered Alectinib 600 mg twice daily by mouth, and Bevacizumab 15 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days).'}, {'id': 'OG001', 'title': 'Phase II: RP2D', 'description': 'In the phase II portion of the study, all patients received alectinib plus bevacizumab at the RP2D determined in the phase I portion.'}], 'classes': [{'categories': [{'measurements': [{'value': '23.87', 'groupId': 'OG000', 'lowerLimit': '10.36', 'upperLimit': '40.52'}, {'value': '7.21', 'groupId': 'OG001', 'lowerLimit': '3.44', 'upperLimit': '27.51'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'up to 4 years', 'description': 'Progression-free survival (PFS) is defined as the time from the start of study treatment to the date of progressive disease (PD) in the central nervous system (CNS) or death due to CNS disease. PD is evaluated using a modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria for CNS response:\n\n\\* PD = At least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. At least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions also qualifies as PD.', 'unitOfMeasure': 'months', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Overall Objective Response Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg', 'description': 'Participants were administered Alectinib 600 mg twice daily by mouth, and Bevacizumab 15 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days).'}, {'id': 'OG001', 'title': 'Phase II: RP2D', 'description': 'In the phase II portion of the study, all patients received alectinib plus bevacizumab at the RP2D determined in the phase I portion.'}], 'classes': [{'categories': [{'measurements': [{'value': '83.33', 'groupId': 'OG000'}, {'value': '60.00', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Up to 4 years', 'description': 'Objective response rate (ORR) is defined as the percentage of participants with intra- and extra-cranial complete response (CR) or partial response (PR), evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1.\n\n* CR = Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to less than 10 mm.\n* PR = At least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Overall Disease Control Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg', 'description': 'Participants were administered Alectinib 600 mg twice daily by mouth, and Bevacizumab 15 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days).'}, {'id': 'OG001', 'title': 'Phase II: RP2D', 'description': 'In the phase II portion of the study, all patients received alectinib plus bevacizumab at the RP2D determined in the phase I portion.'}], 'classes': [{'categories': [{'measurements': [{'value': '100', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Up to 4 years', 'description': 'Disease control rate (DCR) is the percentage of participants with intra- and extra-cranial complete response (CR), partial response (PR), and stable disease (SD), evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version1.1:\n\n* CR = Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to less than 10 mm.\n* PR = At least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters.\n* SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the baseline sum diameters.\n* PD = At least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. At least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions also qualifies as PD.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Progression-free Survival', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg', 'description': 'Participants were administered Alectinib 600 mg twice daily by mouth, and Bevacizumab 15 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days).'}, {'id': 'OG001', 'title': 'Phase II: RP2D', 'description': 'In the phase II portion of the study, all patients received alectinib plus bevacizumab at the RP2D determined in the phase I portion.'}], 'classes': [{'categories': [{'measurements': [{'value': '23.64', 'groupId': 'OG000', 'lowerLimit': '9.02', 'upperLimit': '40.52'}, {'value': '4.95', 'groupId': 'OG001', 'lowerLimit': '4.26', 'upperLimit': '27.51'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'up to 4 years', 'description': 'Progression-free survival (PFS) is defined as the time from the start of study treatment to the date of progressive disease (PD) or death due to any cause. PD is evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version1.1:\n\n\\- PD = At least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. At least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions also qualifies as PD.', 'unitOfMeasure': 'months', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Health-related Quality of Life Questionnaire EORTC QLQ-C30', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg', 'description': 'Participants were administered Alectinib 600 mg twice daily by mouth, and Bevacizumab 15 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days).'}, {'id': 'OG001', 'title': 'Phase II: RP2D', 'description': 'In the phase II portion of the study, all patients received alectinib plus bevacizumab at the RP2D determined in the phase I portion.'}], 'classes': [{'title': 'Baseline: Functional scales', 'categories': [{'measurements': [{'value': '86.67', 'groupId': 'OG000', 'lowerLimit': '77.78', 'upperLimit': '95.56'}, {'value': '42.22', 'comment': 'not applicable for a single participant', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Cycle7: Functional scales', 'categories': [{'measurements': [{'value': '87.78', 'groupId': 'OG000', 'lowerLimit': '82.22', 'upperLimit': '93.33'}, {'value': '68.89', 'comment': 'not applicable for a single participant', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Baseline: Symptom scales', 'categories': [{'measurements': [{'value': '15.38', 'groupId': 'OG000', 'lowerLimit': '12.83', 'upperLimit': '17.95'}, {'value': '38.46', 'comment': 'not applicable for a single participant', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Cycle7: Symptom scales', 'categories': [{'measurements': [{'value': '12.83', 'groupId': 'OG000', 'lowerLimit': '7.69', 'upperLimit': '17.94'}, {'value': '30.77', 'comment': 'not applicable for a single participant', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Baseline: Global health status/QOL', 'categories': [{'measurements': [{'value': '75.00', 'groupId': 'OG000', 'lowerLimit': '66.67', 'upperLimit': '83.33'}, {'value': '25.00', 'comment': 'not applicable for a single participant', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Cycle7: Global health status/QOL', 'categories': [{'measurements': [{'value': '58.33', 'groupId': 'OG000', 'lowerLimit': '50', 'upperLimit': '66.67'}, {'value': '75.00', 'comment': 'not applicable for a single participant', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline to cycle 7 (21 weeks)', 'description': "The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) is designed to measure cancer patients' physical, psychological and social functions. The questionnaire is composed of functional scales, symptom scales, a global health status/quality of life (QOL) scale. All of the scales range in score from 0 to 100. A summary score is calculated as the average of all scores. High score for functional scales mean high level of functioning. High score for global health status means high quality of life. High score for symptom scales mean high level of problems.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Only participants who completed the baseline questionnaire and C7D1 post-treatment questionnaire will be included in the analysis.'}, {'type': 'SECONDARY', 'title': 'Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg', 'description': 'Participants were administered Alectinib 600 mg twice daily by mouth, and Bevacizumab 15 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days).'}, {'id': 'OG001', 'title': 'Phase II: RP2D', 'description': 'In the phase II portion of the study, all patients received alectinib plus bevacizumab at the RP2D determined in the phase I portion.'}], 'classes': [{'title': 'Baseline: Future uncertainty', 'categories': [{'measurements': [{'value': '38.89', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '66.67'}, {'value': '58.33', 'comment': 'not applicable for a single participant', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Cycle7: Future uncertainty', 'categories': [{'measurements': [{'value': '16.67', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '33.33'}, {'value': '33.33', 'comment': 'not applicable for a single participant', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Baseline: Visual disorder', 'categories': [{'measurements': [{'value': '7.41', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '22.22'}, {'value': '0.00', 'comment': 'not applicable for a single participant', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Cycle7: Visual disorder', 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '0.00', 'comment': 'not applicable for a single participant', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Baseline: Motor dysfunction', 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '22.22', 'comment': 'not applicable for a single participant', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Cycle7: Motor dysfunction', 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '11.11', 'comment': 'not applicable for a single participant', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Baseline: Communication deficit', 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '0'}, {'value': '77.78', 'comment': 'not applicable for a single participant', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Cycle7: Communication deficit', 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '00.00'}, {'value': '100.00', 'comment': 'not applicable for a single participant', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Baseline: other symptoms', 'categories': [{'measurements': [{'value': '9.52', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '19.05'}, {'value': '19.05', 'comment': 'not applicable for a single participant', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Cycle7: other symptoms', 'categories': [{'measurements': [{'value': '15.87', 'groupId': 'OG000', 'lowerLimit': '9.52', 'upperLimit': '28.57'}, {'value': '19.05', 'comment': 'not applicable for a single participant', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Cycle 7 Day 1 (21 weeks)', 'description': 'The European Organization for Research and Treatment of Cancer quality of life questionnaire has a brain cancer nodule (EORTC QLQ-BN20) developed for patients undergoing chemotherapy or radiotherapy. It includes 20 items, 13 of which aggregate into four scales assessing future uncertainty, visual disorder, motor dysfunction, and communication deficit. The remaining single items assess other disease symptoms (e.g. headaches and seizures) and treatment toxic effects (e.g. hair loss). Raw scores items were computed and subsequently transformed linearly to a 0-100 scale. A higher score represents worse quality of life.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Only participants who completed the baseline questionnaire and C7D1 questionnaire will be included in the analysis.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg', 'description': 'Participants were administered Alectinib 600 mg twice daily by mouth, and Bevacizumab 15 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days).'}, {'id': 'FG001', 'title': 'Phase I Dose Level -1: Alectinib 600 mg + Bevacizumab 7.5 mg/kg', 'description': 'Participants were administered Alectinib 600 mg twice daily by mouth, and Bevacizumab 7.5 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days).'}, {'id': 'FG002', 'title': 'Phase I Dose Level -2: Alectinib 450 mg + Bevacizumab 7.5 mg/kg', 'description': 'Participants were administered Alectinib 450 mg twice daily by mouth, and Bevacizumab 7.5 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days).'}, {'id': 'FG003', 'title': 'Phase II: RP2D', 'description': 'In the phase II portion of the study, all patients received alectinib plus bevacizumab at the RP2D determined in the phase I portion.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '5'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '5'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '11', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg', 'description': 'Participants were administered Alectinib 600 mg twice daily by mouth, and Bevacizumab 15 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days).'}, {'id': 'BG001', 'title': 'Phase II: RP2D', 'description': 'In the phase II portion of the study, all patients received alectinib plus bevacizumab at the RP2D determined in the phase I portion.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '42', 'groupId': 'BG000', 'lowerLimit': '32', 'upperLimit': '64'}, {'value': '50', 'groupId': 'BG001', 'lowerLimit': '25', 'upperLimit': '66'}, {'value': '46', 'groupId': 'BG002', 'lowerLimit': '25', 'upperLimit': '66'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'years', 'dispersionType': 'FULL_RANGE'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Smoking status', 'classes': [{'title': 'Never', 'categories': [{'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}]}]}, {'title': 'Light (less than 10 pack-years)', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Brain metastases', 'classes': [{'title': 'Present', 'categories': [{'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}]}]}, {'title': 'Absent', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Eastern Cooperative Oncology Group (ECOG) performance status', 'classes': [{'title': 'Score 0', 'categories': [{'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}]}]}, {'title': 'Score 1', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}]}]}, {'title': 'Score 2', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': "ECOG performance score assesses a participant's level of function and capability of self-care. Scores range from 0 to 5, with higher scores indicating lower levels of function. Study eligibility criteria allowed participants with ECOG scores 0-2 to be enrolled.\n\n* Score 0 = Fully active, asymptomatic.\n* Score 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g. light housework, office work.\n* Score 2 = Ambulatory and capable of all self-care but unable to carry out any work activities, in bed \\<50% of waking hours", 'unitOfMeasure': 'Participants'}, {'title': 'Prior anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) therapy', 'classes': [{'title': 'Yes', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}]}]}, {'title': 'No', 'categories': [{'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2020-10-07', 'size': 894969, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2023-03-07T13:57', 'hasProtocol': True}, {'date': '2019-03-26', 'size': 1847693, 'label': 'Informed Consent Form: Phase 1 consent', 'hasIcf': True, 'hasSap': False, 'filename': 'ICF_001.pdf', 'typeAbbrev': 'ICF', 'uploadDate': '2023-03-07T13:58', 'hasProtocol': False}, {'date': '2020-12-28', 'size': 689571, 'label': 'Informed Consent Form: Phase 2 consent', 'hasIcf': True, 'hasSap': False, 'filename': 'ICF_002.pdf', 'typeAbbrev': 'ICF', 'uploadDate': '2023-03-10T16:58', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 11}}, 'statusModule': {'whyStopped': 'slow accrual', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2015-09-28', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-04', 'completionDateStruct': {'date': '2022-04', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-04-25', 'studyFirstSubmitDate': '2015-07-20', 'resultsFirstSubmitDate': '2023-03-10', 'studyFirstSubmitQcDate': '2015-08-07', 'lastUpdatePostDateStruct': {'date': '2025-05-13', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2025-04-25', 'studyFirstPostDateStruct': {'date': '2015-08-13', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2025-05-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-04', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': '(Phase 1) Recommended Phase II Dose of Alectinib', 'timeFrame': 'first cycle of treatment (21 days)', 'description': 'The recommended phase II doses for the combination of alectinib and bevacizumab will be defined as either a) the highest dosage cohort in which less than 1/3 of patients experience a dose-limiting toxicity or b) alectinib at the previously defined recommended phase II dose (600 mg twice daily PO) as a single agent plus bevacizumab at the highest tolerated dose (15 mg/kg IV every 21 days) investigated in this indication - whichever is the lower dose.\n\nDose-limiting toxicities (DLTs) were defined as adverse events (AEs) occurring within the first cycle of treatment (21 days) attributed to the study drugs.'}, {'measure': '(Phase 1) Recommended Phase II Dose of Bevacizumab', 'timeFrame': 'first cycle of treatment (21 days)', 'description': 'The recommended phase II doses for the combination of alectinib and bevacizumab will be defined as either a) the highest dosage cohort in which less than 1/3 of patients experience a dose-limiting toxicity or b) alectinib at the previously defined recommended phase II dose (600 mg twice daily PO) as a single agent plus bevacizumab at the highest tolerated dose (15 mg/kg IV every 21 days) investigated in this indication - whichever is the lower dose.\n\nDose-limiting toxicities (DLTs) were defined as adverse events (AEs) occurring within the first cycle of treatment (21 days) attributed to the study drugs.'}, {'measure': '(Phase 2) Number of Participants With Intracranial Hemorrhagic Events Who Received RP2D', 'timeFrame': 'up to 4 years', 'description': 'In the phase II portion of the study, we aim to further investigate the safety and tolerability of alectinib plus bevacizumab at the RP2Ds as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The combination of alectinib and bevacizumab will be deemed unsafe if 2 or more participants are observed to have grade 2 or higher, central nervous system (CNS) intracranial hemorrhagic events.'}], 'secondaryOutcomes': [{'measure': 'Central Nervous System Objective Response Rate', 'timeFrame': 'Up to 4 years', 'description': 'Objective response rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR), evaluated using a modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria for CNS response:\n\n* CR = Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to less than 10 mm.\n* PR = At least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters.'}, {'measure': 'Central Nervous System Disease Control Rate', 'timeFrame': 'Up to 4 years', 'description': 'Disease control rate (DCR) is the percentage of participants with intracranial complete response (CR), partial response (PR), and stable disease (SD), evaluated using a modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria for CNS response:\n\n* CR = Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to less than 10 mm.\n* PR = At least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters.\n* SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the baseline sum diameters.\n* PD = At least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. At least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions also qualifies as PD.'}, {'measure': 'Central Nervous System Progression-free Survival', 'timeFrame': 'up to 4 years', 'description': 'Progression-free survival (PFS) is defined as the time from the start of study treatment to the date of progressive disease (PD) in the central nervous system (CNS) or death due to CNS disease. PD is evaluated using a modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria for CNS response:\n\n\\* PD = At least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. At least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions also qualifies as PD.'}, {'measure': 'Overall Objective Response Rate', 'timeFrame': 'Up to 4 years', 'description': 'Objective response rate (ORR) is defined as the percentage of participants with intra- and extra-cranial complete response (CR) or partial response (PR), evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1.\n\n* CR = Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to less than 10 mm.\n* PR = At least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters.'}, {'measure': 'Overall Disease Control Rate', 'timeFrame': 'Up to 4 years', 'description': 'Disease control rate (DCR) is the percentage of participants with intra- and extra-cranial complete response (CR), partial response (PR), and stable disease (SD), evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version1.1:\n\n* CR = Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to less than 10 mm.\n* PR = At least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters.\n* SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the baseline sum diameters.\n* PD = At least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. At least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions also qualifies as PD.'}, {'measure': 'Progression-free Survival', 'timeFrame': 'up to 4 years', 'description': 'Progression-free survival (PFS) is defined as the time from the start of study treatment to the date of progressive disease (PD) or death due to any cause. PD is evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version1.1:\n\n\\- PD = At least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the baseline sum diameters. At least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions also qualifies as PD.'}, {'measure': 'Health-related Quality of Life Questionnaire EORTC QLQ-C30', 'timeFrame': 'Baseline to cycle 7 (21 weeks)', 'description': "The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) is designed to measure cancer patients' physical, psychological and social functions. The questionnaire is composed of functional scales, symptom scales, a global health status/quality of life (QOL) scale. All of the scales range in score from 0 to 100. A summary score is calculated as the average of all scores. High score for functional scales mean high level of functioning. High score for global health status means high quality of life. High score for symptom scales mean high level of problems."}, {'measure': 'Health-related Quality of Life Questionnaire Specific to Brain Cancer: EORTC QLQ-BN20', 'timeFrame': 'Baseline, Cycle 7 Day 1 (21 weeks)', 'description': 'The European Organization for Research and Treatment of Cancer quality of life questionnaire has a brain cancer nodule (EORTC QLQ-BN20) developed for patients undergoing chemotherapy or radiotherapy. It includes 20 items, 13 of which aggregate into four scales assessing future uncertainty, visual disorder, motor dysfunction, and communication deficit. The remaining single items assess other disease symptoms (e.g. headaches and seizures) and treatment toxic effects (e.g. hair loss). Raw scores items were computed and subsequently transformed linearly to a 0-100 scale. A higher score represents worse quality of life.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Non-Small Cell Lung Cancer (NSCLC)', 'Anaplastic lymphoma kinase', 'ALK', 'Brain metastases'], 'conditions': ['Non-Small Cell Lung Cancer (NSCLC)']}, 'descriptionModule': {'briefSummary': 'This research study is evaluating two drugs, alectinib and bevacizumab, as possible treatments for Advanced Non-Small Cell Lung Cancer (NSCLC).', 'detailedDescription': 'This is a Phase I/II clinical trial.\n\n* A Phase I clinical trial tests the safety of an investigational intervention and also tries to define the appropriate dose(s) of the investigational intervention to use for further studies.\n* Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease.\n* "Investigational" means that the intervention is being studied.\n\n * In this research study, the investigators are investigating the combination of two study drugs: alectinib and bevacizumab. The FDA (the U.S. Food and Drug Administration) has not approved alectinib as a treatment for any disease.\n\nIt has been found that some people with NSCLC have a change (mutation) in a certain gene called the anaplastic lymphoma receptor tyrosine kinase (ALK) gene. This mutated gene helps cancer cells grow.\n\n\\-- Alectinib belongs to a class of drugs designed to inhibit ALK. This drug has been used in other research studies. Information from those other research studies suggests that alectinib may be effective in killing cancer cells that have changes in ALK. Only participants with changes in the ALK gene will be allowed to participate in this study.\n\nIn this research study, Alectinib will be combined with Bevacizumab. -- Bevacizumab (also called Avastin) works by slowing or stopping the growth of cells in cancer tumors by decreasing the blood supply of the tumors. If blood supply is decreased, oxygen and nutrients that are needed for tumor growth are decreased. The FDA has approved Bevacizumab as a treatment option for your disease\n\nThe purpose of this study is to test the safety of Alectinib and Bevacizumab. The investigators will also determine how effective this combination is in participants with advanced, ALK-positive NSCLC with a focus on participants with brain metastases.\n\nIn the phase I portion of the study, a 3 + 3 dose de-escalation design was to determine the recommended phase II dose (RP2D) of alectinib and bevacizumab. Three patients will be treated per cohort for one cycle (21 days per cycle) beginning with dose level 1 cohort.\n\n* Dose level 1 (starting dose) = Alectinib 600mg twice daily orally (PO), and Bevacizumab 15 mg/kg administered intravenously (IV) every 3 weeks.\n\n \\-- Dose level 1 was selected based on the individual RP2Ds for each medication and anticipation for minimal overlapping toxicities.\n* Dose level -1 = Alectinib 600mg twice daily orally (PO),and Bevacizumab 7.5 mg/kg administered intravenously (IV) every 3 weeks.\n* Dose level -2 = Alectinib 450mg twice daily orally (PO), and Bevacizumab 7.5 mg/kg administered intravenously (IV) every 3 weeks.\n\nDLTs were defined as adverse events (AEs) occurring within the first cycle of treatment (21 days) attributed to the study drugs, and grade 3 or higher according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. If no DLTs are observed with dose level 1 cohort, we will enroll an additional 3 participants (6 total) to the same cohort and proceed with the phase II portion of the study if one or less experience a DLT. In any other dose level cohort, if one of three patients experiences a DLT, another 3 patients will be treated at the same dose level for one cycle. If no additional DLTs are observed, we will proceed with the phase II portion of the trial. If more than one of 3 patients develops a DLT in any cohort, another 3 patients will be treated in the next lowest dose cohort.\n\nThe RP2D for the combination of alectinib and bevacizumab was defined as either (i) the highest dosage cohort in which less than a third of patients experienced a DLT, or (ii) alectinib at the previously defined RP2D as a single agent (600 mg twice daily) plus bevacizumab at the highest tolerated dose investigated for the indication (15 mg/kg every 21 days), whichever was the lower dose.\n\nIn the phase II portion of the study, all patients received alectinib plus bevacizumab at the RP2D determined in the phase I portion. Cycles were 21 days long. Treatment was continued until there was evidence of progressive disease, death, or unacceptable toxicity. Patients were allowed to continue study drugs beyond progression if deemed clinically beneficial at the investigator\'s discretion. Intra-patient dose modification of bevacizumab was not permitted.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Histologically or cytologically confirmed advanced, non-squamous, non-small cell lung cancer.\n* Molecular confirmation of an ALK rearrangement.\n* Age ≥ 18 years old.\n* Life expectancy \\> 12 weeks.\n* Performance status 0-2.\n* Adequate hematologic function:\n* Adequate renal function:\n\n * An estimated Glomerular Filtration Rate (eGFR) of at least 45 mL/min/1.73 m2\n * International normalized ration (INR)≤ 1.5\n * Partial thromboplastin time (PTT) ≤1.5 x upper limit of normal (ULN)\n* For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment.\n* Able and willing to provide written informed consent\n* Phase II Only:\n* Presence of at least one measurable central nervous system (CNS) target lesion (At least 5 mm in size)\n\n * Lesions must be untreated or progressive according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 after previous local therapy.\n * Participants who are receiving corticosteroids must be on a stable or decreasing dose\n* At least one measurable extra-CNS lesion based upon RECIST version 1.1.\n\nExclusion Criteria:\n\n* Squamous cell histology or mixed, predominantly squamous adenosquamous carcinoma\n* Previous history of haemoptysis\n* Tumour infiltrating into large vessels or infiltrating into the proximal tracheobronchial network\n* Unstable, symptomatic brain metastases.\n* History of hemorrhagic CNS metastases\n* History of intracranial hemorrhage (either by clinical history or neuroimaging)\n* History of or genetic predisposition to a bleeding diathesis or coagulopathy\n* Therapeutic anticoagulation\n* Current or recent (within 10 days of first dose of bevacizumab) use of aspirin (\\> 325 mg/day)\n* Clinically significant heart disease (i.e., active), stroke or myocardial infarction within 6 months prior to enrolment, unstable angina pectoris, congestive heart failure of grade \\> II according to the New York Heart Association (NYHA), or cardiac arrhythmia requiring specific treatment\n* Arterial or venous thromboembolic events within 6 months of study enrollment.\n* Poorly controlled arterial hypertension (systolic \\> 150 mm Hg and/or diastolic \\> 100 mm Hg)\n* Invasive surgical intervention within 28 days prior to the start of treatment\n* Minor surgical intervention, including placement of a permanent catheter within 24 hours prior to the first infusion of bevacizumab.\n* Non-healing wound, active peptic ulcer or bone fracture.\n* Previous history of abdominal fistula, tracheoesophageal fistula or other fistula with grade 4 severity, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to enrolment.\n* Proteinuria at baseline.\n* Previous anti-angiogenic treatment\n* Patients previously treated with alectinib (Phase II only).\n* Radical radiotherapy to the thorax with curative intent within 28 days\n* Cytotoxic chemotherapy within 21 days prior to enrolment.\n* Treatment with crizotinib within 7 days prior to enrolment. For all other ALK Tyrosine kinase inhibitors (TKIs), the washout period should be ≥5 half-lives prior to enrolment.\n* Any GI disorder that may affect absorption of oral medications\n* Alanine transaminase (ALT) or aspartate transaminase (AST) \\> 3 × ULN (≥5 × ULN for patients with concurrent liver metastasis)\n* Impaired excretory function (e.g., hyperbilirubinemia) or synthetic function or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices\n* Acute viral or active autoimmune, alcoholic, or other types of hepatitis\n* National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (version 4.0) Grade 3 or higher toxicities due to any prior therapy (e.g. radiotherapy) (excluding alopecia),\n* History of organ transplant.\n* Co-administration of anti-cancer therapies other than those administered in this study.\n* QTc \\> 470 ms or patients with symptomatic bradycardia.\n* Administration of strong/potent cytochrome P450 (CYP)3A inhibitors or inducers within 14 days\n* Administration of agents with potential QT interval prolonging effects within 14 days prior to the first administration of study drug and while on treatment.\n* History of hypersensitivity to any of the additives in the alectinib drug formulation\n* Documented allergy or hypersensitivity to monoclonal antibodies (bevacizumab)\n* History of drug-induced pneumonitis or hypersensitivity pneumonitis from prior ALK TKI therapy.\n* Pregnant or lactating women.\n* Known HIV positivity or AIDS-related illness.\n* Any condition or illness that could compromise patient safety or interfere with the evaluation of the study drugs.'}, 'identificationModule': {'nctId': 'NCT02521051', 'briefTitle': 'Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer', 'organization': {'class': 'OTHER', 'fullName': 'Massachusetts General Hospital'}, 'officialTitle': 'A Phase I/II Trial to Evaluate the Safety and Tolerability of Alectinib and Bevacizumab in Patients With Advanced, ALK-Positive, Non-Small Cell Lung Cancer', 'orgStudyIdInfo': {'id': '15-055'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg', 'description': 'Participants were administered Alectinib 600 mg twice daily by mouth, and Bevacizumab 15 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days).', 'interventionNames': ['Drug: Alectinib', 'Drug: Bevacizumab']}, {'type': 'EXPERIMENTAL', 'label': 'Phase I Dose Level -1: Alectinib 600 mg + Bevacizumab 7.5 mg/kg', 'description': 'Participants were administered Alectinib 600 mg twice daily by mouth, and Bevacizumab 7.5 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days).', 'interventionNames': ['Drug: Alectinib', 'Drug: Bevacizumab']}, {'type': 'EXPERIMENTAL', 'label': 'Phase I Dose Level -2: Alectinib 450 mg + Bevacizumab 7.5 mg/kg', 'description': 'Participants were administered Alectinib 450 mg twice daily by mouth, and Bevacizumab 7.5 mg/kg intravenously once every 3 weeks. DLTs will be monitored and evaluated throughout the first cycle (21 days).', 'interventionNames': ['Drug: Alectinib', 'Drug: Bevacizumab']}, {'type': 'EXPERIMENTAL', 'label': 'Phase II: RP2D', 'description': 'In the phase II portion of the study, all patients received alectinib plus bevacizumab at the RP2D determined in the phase I portion.', 'interventionNames': ['Drug: Alectinib', 'Drug: Bevacizumab']}], 'interventions': [{'name': 'Alectinib', 'type': 'DRUG', 'otherNames': ['Alecensa'], 'armGroupLabels': ['Phase I Dose Level -1: Alectinib 600 mg + Bevacizumab 7.5 mg/kg', 'Phase I Dose Level -2: Alectinib 450 mg + Bevacizumab 7.5 mg/kg', 'Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg', 'Phase II: RP2D']}, {'name': 'Bevacizumab', 'type': 'DRUG', 'otherNames': ['Avastin'], 'armGroupLabels': ['Phase I Dose Level -1: Alectinib 600 mg + Bevacizumab 7.5 mg/kg', 'Phase I Dose Level -2: Alectinib 450 mg + Bevacizumab 7.5 mg/kg', 'Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg', 'Phase II: RP2D']}]}, 'contactsLocationsModule': {'locations': [{'zip': '02115', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Massachusetts General Hospital', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}], 'overallOfficials': [{'name': 'Justin Gainor, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Massachusetts General Hospital'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Massachusetts General Hospital', 'class': 'OTHER'}, 'collaborators': [{'name': 'Genentech, Inc.', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator', 'investigatorFullName': 'Justin Gainor, MD', 'investigatorAffiliation': 'Massachusetts General Hospital'}}}}